In a phase 2 decentralized study, once-daily trientine tetrahydrochloride improved convenience and adherence in Wilson disease; 80% preferred it.
|Videos|September 8, 2016
Alexis LaPietra, DO: Treating Acute Pain in Emergency Medicine
Author(s)Amy Jacob
Pain management is everyone's job. It's a human problem.
Advertisement
At PAINWeek 2016, Alexis LaPietra, D, St. Joseph's Medical Center spoke about case scenarios and not getting fooled by first impressions - that patient populations can be different.
LaPietra also discussed the significance of PAINWeek - how it's a collaboration among practitioners, pharmacists, and a variety of other specialists, which shows pain management is everyone's job. It's a human problem.
Advertisement
Related to this article
Type 2 biologics reduced mucus plugs in asthma trials, and quantitative imaging may help detect this treatable phenotype, according to a GOLD 2026 session.
In adults with late-onset PFIC, odevixibat improved pruritus within 3 months in a real-world study at presented at The Liver Meeting 2026.
CT-detected mucus plugs affect up to 67% of patients with COPD and are linked to worse lung function, exacerbations, and mortality, even without symptoms.
At GOLD 2026, Alvar AgustĂ, MD, PhD, speaks on COPD underdiagnosis and misdiagnosis, barriers to spirometry in primary care, and managing pre-COPD.
Carla Nester, MD, discusses sustained proteinuria reduction and kidney function findings through 76 weeks of pegcetacoplan treatment.
Real-world data at AASLD 2026 show 37% to 55% of patients with MASH on resmetirom (Rezdiffra) improved liver stiffness by 25% or more at about one year.
In the phase 3 IDEAL trial, 3 in 4 patients with PBC and ALP below 1.67Ă— ULN reached ALP normalization on seladelpar at 52 weeks, compared with 16.1% on placebo.
Advertisement
Advertisement
Trending on HCPLive
1
Real-World Resmetirom Data Show Liver Stiffness Gains in MASH
2
IDEAL: Seladelpar Achieves ALP Normalization in Second-Line PBC
3
Conference Preview: 2026 GOLD International COPD Conference
4
Oral STAT6 Degrader KT-621 Reduces EASI by 62.6% in Atopic Dermatitis
5